Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2, Sirolimus, and Tacrolimus for GVHD Prophylaxis
NCT01927120Phase 2Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Mar 2014
- Primary completion
- Aug 2016
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in graft-versus-host disease (GVHD), sponsored by Moffitt Cancer Center. Started Mar 2014; status: completed.
02
Drugs
aldesleukin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT01927120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01927120.